Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, invariably fatal fibrotic lung disease with no lasting option for therapy. Mesenchymal stem cells (MSCs) could be a promising modality for the treatment of IPF. Aim of the study was to investigate improvement in survivability and anti-fibrotic efficacy of human adipose-derived mesenchymal stem cells (AD-MSCs) in comparison with pirfenidone in the bleomycin-induced pulmonary fibrosis model.

中文翻译：

---

人脂肪来源的间充质干细胞减弱博莱霉素诱导的肺纤维化的早期阶段：与吡非尼酮的比较。

特发性肺纤维化 (IPF) 是一种进行性、不可逆、总是致命的纤维化肺病，没有持久的治疗选择。间充质干细胞 (MSCs) 可能是治疗 IPF 的一种有前途的方式。该研究的目的是研究在博莱霉素诱导的肺纤维化模型中，与吡非尼酮相比，人脂肪来源的间充质干细胞 (AD-MSCs) 的生存能力和抗纤维化功效的改善情况。